|
|
|
|
The MDS Foundation Says Newly Published Study Finds Vidaza Prolongs Survival in Acute Myeloid Leukemia
Publication Could Encourage Physicians to Offer Treatment to Patients with this Difficult Cancer CROSSWICKS, N.J.--(BUSINESS WIRE)--Feb 2, 2010 - The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology...
|
|
|
VIDAZA prolongs survival in AML patients
The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) prolongs survival and is well tolerated in patients with acute myeloid leukemia (AML) - an aggressive form...
|
|
|
The MDS Foundation Says Newly Published Study Finds VIDAZA Prolongs Survival in Acute Myeloid Leukemia
CROSSWICKS, N.J.--(BUSINESS WIRE)--The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) ?prolongs survival and is well tolerated?in patients with acute...
|
|
|
Epigenetics Offers Strategies for New Drugs
Mechanisms of action of different histone-modifying enzymes (CellCentric) Increasing numbers of scientists are focusing their studies on epigenetics to get a better handle on how internal and external factors lead to cellular malfunctioning and impact the...
|
|
|
Epigenetics Offers Strategies for New Drugs
click to enlarge Mechanisms of action of different histone-modifying enzymes (CellCentric) Increasing numbers of scientists are focusing their studies on epigenetics to get a better handle on how internal and external factors lead to cellular malfunctioning and...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q - VIDAZA Fourth Quarter Global Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
- Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals - REVLIMID Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q - VIDAZA Fourth Quarter Global Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
Companies mentioned in this article: Celgene Corporation SUMMIT, N.J.-- (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased 35...
|
|
|
Celgene reports total revenue of $758M for fourth-quarter of 2009
Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased 35 Percent to $497 Million Global VIDAZA Net Product Sales Increased 68 Percent to $117 Million Global THALOMID Net...
|
|
|
Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income
SUMMIT, N.J.- (BUSINESS WIRE) - Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $761 Million Global REVLIMID Net Product Sales Increased...
|
|
|
Celgene Sees 4Q Profit On Sales Boost, Lower Costs
SUMMIT, N.J.--Biotech drugmaker Celgene Corp.on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million,...
|
|
|
Celgene reports 4th-quarter profit on cancer drug sales boost, lower research costs
SUMMIT, N.J.Biotech drugmaker Celgene Corp. on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million,...
|
|
|
Celgene Corporation (NASDAQ:CELG) Acquires Cloucester Pharmaceuticals
Rochester, New York 1/18/2010 09:30 PM GMT (TransWorldNews) Celgene Corporation (NASDAQ:CELG) has announced that it has acquired Gloucester Pharmaceuticals.The transaction closed for $340 million, after the early termination of the applicable waiting period...
|
|
|
Celgene Expands In Cancer Drugs
Recently, Celgene Corporation (CELG) completed the acquisition of the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments.The deal is aimed at bolstering Celgenes portfolio of cancer drugs...
|
|
|
Celgene completes acquisition of Gloucester Pharma
Celgene Corporation has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger agreement Celgene...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.-- (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements...
|
|
|
Celgene completes acquisition of Gloucester Pharmaceuticals
--Celgene Corporation announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
(Source: Business Wire)Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.- (BUSINESS WIRE) - Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
